HJ-099 / Chengdu Huajian Future Science and Technology - LARVOL DELTA

HJ-099, a novel, orally bioavailable pan-KRAS (ON) non-covalent inhibitor, demonstrates significant antitumor activity in multiple preclinical models with KRAS mutations (AACR 2025) - "The study indicates that HJ-099 is a novel, highly active pan-KRAS (ON) inhibitor that shows significant tumor suppression activity against major KRAS mutation subtypes, and merits clinical evaluation."

Preclinical • Oncology • KRAS